


Mepolizumab in severe uncontrolled CRSwNP: a real-life multicentre study in Northeast Italy



Patient & physician derived outcome measures



Patients receiving mepolizumab as add-on therapy for severe uncontrolled CRSwNP





♀ 33

♂ 57



12

Mepolizumab effectiveness




Significant improvement within first month of treatment

Benefit maintained at subsequent follow-ups



Discontinuation of treatment

Lack of benefit within 1 year



No major adverse events reported



Safely enhancing patient QoL:

↓ Nasal obstruction

↓ Nasal polyp size

↑ Olfactory function